The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
Publications
Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review.
Medicina (Kaunas, Lithuania) 2020 Apr 24;56; — 2020 Apr 24
de Oliveira Uehara SN, Emori CT, Perez RM, Mendes-Correa MC, de Souza Paiva Ferreira A, de Castro Amaral Feldner AC, Silva AE, Filho RJ, de Souza E Silva IS, Ferraz ML
High incidence of tuberculosis in patients treated for hepatitis C chronic infection.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2016 Mar-Apr;20;205-9 — 2016 Mar-Apr — 205-9
Fukuba R, Kawaratani H, Kubo T, Kaya D, Aihara Y, Morioka C, Noguchi R, Mitoro A, Yoshiji H, Fukui H
Tuberculous peritonitis during pegylated interferon plus ribavirin combination therapy in a patient with chronic hepatitis C.
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2014 12;111;2337-45 — 2014 12 — 2337-45
Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis.
Scandinavian journal of infectious diseases 2006;38;205-8 — 2006 — 205-8